Endothelin Blockade in Diabetic Kidney Disease.

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease.
• Current therapies targeting the renin-angiotensin system offer only partial effectiveness.
• Endothelin-1 (ET-1) plays a significant role in diabetes-related renal injury and fibrosis.

Purpose of the Study:

• To review the localization and function of endothelin receptors (ETA and ETB) in the kidney.
• To summarize the therapeutic potential of endothelin receptor antagonists in DKD.
• To discuss findings from experimental and clinical studies of these antagonists.

Main Methods:

• Review of existing literature on endothelin receptor antagonists in DKD.
• Analysis of experimental models of DKD.
• Examination of clinical trial data in human subjects with DKD.

Main Results:

• Endothelin receptor antagonists have demonstrated improvements in renal injury and fibrosis in experimental DKD models.
• Clinical trials indicate an antiproteinuric effect of these antagonists in DKD patients.
• Ongoing clinical trials are evaluating long-term renoprotective effects.

Conclusions:

• Endothelin receptor antagonists represent a promising therapeutic strategy for DKD.
• Further clinical evaluation is necessary to confirm long-term renoprotective benefits and assess safety profiles.
• Targeting the endothelin system offers a potential new avenue for managing DKD.